PDCD1 and renal cell adenocarcinoma: Further clinical trial that assessed the activity and safety of nivolumab (previous known as BMS-936558) demonstrated anti-PD-1 antibody produced antitumor responses in melanoma, NSCLC and RCC (Topalian et al., 2012).